EAD (TTM)

EAD/share (TTM)

EAD (Quarter)

EAD/share (Quarter)

Price per share at the end of the period divided by the last reported earnings

Price/EAD

Based in Westbury, NY, ACRES Commercial Realty Corp is a real estate investment trust that is primarily focused on originating, holding and managing commercial real estate mortgage loans and other commercial real estate-related debt investments. The Company is externally managed by ACRES Capital, LLC, a subsidiary of ACRES Capital Corp., a private commercial real estate lender exclusively dedicated to nationwide middle market CRE lending with a focus on multifamily, student housing, hospitality, office, industrial and other asset types in top US markets.

ACRES Commercial Realty

The main earnings metric reported by the REIT

If the REIT is managed by an internal (employees) or external (separate company) team

Period: 2022 Q4

Years since IPO: 15/15,
EAD Growth: 1/15,
EAD/share Growth: 1/20,
Dividend Growth: 5/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2023 Q1

Years since IPO: 15/15,
EAD Growth: 0/15,
EAD/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2023 Q2

Years since IPO: 15/15,
EAD Growth: 0/15,
EAD/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2023 Q3

Years since IPO: 15/15,
EAD Growth: 0/15,
EAD/share Growth: 0/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2023 Q4

Years since IPO: 15/15,
EAD Growth: 6/15,
EAD/share Growth: 11/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2024 Q1

Years since IPO: 15/15,
EAD Growth: 5/15,
EAD/share Growth: 10/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2024 Q2

Years since IPO: 15/15,
EAD Growth: 5/15,
EAD/share Growth: 10/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2024 Q3

Years since IPO: 15/15,
EAD Growth: 5/15,
EAD/share Growth: 10/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2024 Q4

Years since IPO: 15/15,
EAD Growth: 5/15,
EAD/share Growth: 10/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2025 Q1

Years since IPO: 15/15,
EAD Growth: 5/15,
EAD/share Growth: 10/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2025 Q2

Years since IPO: 15/15,
EAD Growth: 5/15,
EAD/share Growth: 10/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

Period: 2025 Q3

Years since IPO: 15/15,
EAD Growth: 5/15,
EAD/share Growth: 10/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 0/15
            

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's EAD

EAD Growth

Assessment of recent increases in EAD per share, indicating profitability

EAD/share Growth

Analysis of the recent Dividend track record

Dividend Growth

Payout level to determine if the dividend is safe

Payout Ratio

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

Shares of ACRES Commercial Realty Corp. (NYSE: ACR - Get Free Report) have received an average recommendation of "Moderate Buy" from the five ratings firms that are currently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The

ACRES Commercial Realty Corp. (NYSE:ACR) Given Average Recommendation of “Moderate Buy” by Analysts

WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify global compound-specific, drug-regulated effects in the intact cell which is deployed for rational drug design and predictive clinical development, today announced it will be providing ACR-368 and ACR-2316 clinical data and other updates via a conference call and webcast in January 2026.

UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast

UNIONDALE, N.Y. , Dec. 15, 2025 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) (the "Company") announced today that its Board of Directors declared cash dividends on its Preferred Stock.

ACRES Commercial Realty Corp. Declares Quarterly Cash Dividends for its Preferred Stock

ACRES Commercial Realty (NYSE: ACR - Get Free Report) and Cherry Hill Mortgage Investment (NYSE: CHMI - Get Free Report) are both small-cap finance companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations. Volatility and Risk ACRES

Contrasting Cherry Hill Mortgage Investment (NYSE:CHMI) & ACRES Commercial Realty (NYSE:ACR)

/PRNewswire/ -- ACR Poker's Dual Venom PKO tournaments have wrapped up in spectacular fashion, smashing guarantees once again, and showing why it's one of the

ACR Poker's Dual Venom PKO Tournaments Deliver Knockout Success, Smashing Guaranteed Prize Pools to Award $7.8 million to Players

UNIONDALE, N.Y. , Oct. 29, 2025 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE:ACR) (the "Company") announced today that its board of directors (the "Board") authorized and approved the continued use of its existing share repurchase program to repurchase an additional $7.5 million of the outstanding shares of both its common and preferred stock.

ACRES Commercial Realty Corp. Reauthorizes an Additional $7.5 Million Share Repurchase Program

UNIONDALE, N.Y. , Oct. 29, 2025 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) ("ACR" or the "Company"), a real estate investment trust that is primarily focused on originating, holding and managing commercial real estate mortgage loans and equity investments in commercial real estate property through direct ownership and joint ventures, today reported results for the quarter ended September 30, 2025.

ACRES COMMERCIAL REALTY CORP. REPORTS RESULTS FOR THIRD QUARTER 2025

SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced late-breaking data from the robust, global 424-patient Phase 2b trial of rosnilimab, a selective and potent pathogenic T cell depleter, in rheumatoid arthritis (RA) at the American College of Rheumatology (ACR) Convergence 2025 in Chicago. New study results showed that positive Week 12 data across multiple higher-order response measures continue to deepen into Week 28 regardless of prior treatment. These results were then durable for at least three months off drug. Additionally, rosnilimab was well-tolerated with no treatment-related serious adverse events and no malignancies in rosnilimab-treated patients through end-of-trial follow-up (Week 38).

Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation

WATERTOWN, MASS., DEC. 17, 2025 (GLOBE NEWSWIRE) -- ACRIVON THERAPEUTICS, INC. (ACRIVON OR ACRIVON THERAPEUTICS) (NASDAQ: ACRV), A CLINICAL STAGE BIOTECHNOLOGY COMPANY DISCOVERING AND DEVELOPING PRECISION MEDICINES UTILIZING ITS PROPRIETARY GENERATIVE PHOSPHOPROTEOMICS AP3 (ACRIVON PREDICTIVE PRECISION PROTEOMICS) PLATFORM DESIGNED TO INTERPRET AND QUANTIFY GLOBAL COMPOUND-SPECIFIC, DRUG-REGULATED EFFECTS IN THE INTACT CELL WHICH IS DEPLOYED FOR RATIONAL DRUG DESIGN AND PREDICTIVE CLINICAL DEVELOPMENT, TODAY ANNOUNCED IT WILL BE PROVIDING ACR-368 AND ACR-2316 CLINICAL DATA AND OTHER UPDATES VIA A CONFERENCE CALL AND WEBCAST IN JANUARY 2026.

UPDATE -- ACRIVON THERAPEUTICS TO ANNOUNCE CLINICAL UPDATE ON ITS ONGOING PHASE 2B STUDIES AND PLANNED CONFIRMATORY PHASE 3 TRIAL FOR ACR-368, INITIAL CLINICAL DATA ON ACR-2316, AND OTHER AP3 PIPELINE UPDATES VIA WEBCAST

UNIONDALE, N.Y. , DEC. 15, 2025 /PRNEWSWIRE/ --ACRES COMMERCIAL REALTY CORP.(NYSE: ACR) (THE "COMPANY") ANNOUNCED TODAY THAT ITS BOARD OF DIRECTORS DECLARED CASH DIVIDENDS ON ITS PREFERRED STOCK.

ACRES COMMERCIAL REALTY CORP. DECLARES QUARTERLY CASH DIVIDENDS FOR ITS PREFERRED STOCK

UNIONDALE, N.Y. , OCT. 29, 2025 /PRNEWSWIRE/ -- ACRES COMMERCIAL REALTY CORP. (NYSE:ACR) (THE "COMPANY") ANNOUNCED TODAY THAT ITS BOARD OF DIRECTORS (THE "BOARD") AUTHORIZED AND APPROVED THE CONTINUED USE OF ITS EXISTING SHARE REPURCHASE PROGRAM TO REPURCHASE AN ADDITIONAL $7.5 MILLION OF THE OUTSTANDING SHARES OF BOTH ITS COMMON AND PREFERRED STOCK.

ACRES COMMERCIAL REALTY CORP. REAUTHORIZES AN ADDITIONAL $7.5 MILLION SHARE REPURCHASE PROGRAM

UNIONDALE, N.Y. , OCT. 29, 2025 /PRNEWSWIRE/ -- ACRES COMMERCIAL REALTY CORP. (NYSE: ACR) ("ACR" OR THE "COMPANY"),A REAL ESTATE INVESTMENT TRUST THAT IS PRIMARILY FOCUSED ON ORIGINATING, HOLDING AND MANAGING COMMERCIAL REAL ESTATE MORTGAGE LOANS AND EQUITY INVESTMENTS IN COMMERCIAL REAL ESTATE PROPERTY THROUGH DIRECT OWNERSHIP AND JOINT VENTURES, TODAY REPORTED RESULTS FOR THE QUARTER ENDED SEPTEMBER30, 2025.

SAN DIEGO, OCT. 29, 2025 (GLOBE NEWSWIRE) -- ANAPTYSBIO, INC. (NASDAQ: ANAB), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DELIVERING INNOVATIVE IMMUNOLOGY THERAPEUTICS, TODAY ANNOUNCED LATE-BREAKING DATA FROM THE ROBUST, GLOBAL 424-PATIENT PHASE 2B TRIAL OF ROSNILIMAB, A SELECTIVE AND POTENT PATHOGENIC T CELL DEPLETER, IN RHEUMATOID ARTHRITIS (RA) AT THE AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) CONVERGENCE 2025 IN CHICAGO. NEW STUDY RESULTS SHOWED THAT POSITIVE WEEK 12 DATA ACROSS MULTIPLE HIGHER-ORDER RESPONSE MEASURES CONTINUE TO DEEPEN INTO WEEK 28 REGARDLESS OF PRIOR TREATMENT. THESE RESULTS WERE THEN DURABLE FOR AT LEAST THREE MONTHS OFF DRUG. ADDITIONALLY, ROSNILIMAB WAS WELL-TOLERATED WITH NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS AND NO MALIGNANCIES IN ROSNILIMAB-TREATED PATIENTS THROUGH END-OF-TRIAL FOLLOW-UP (WEEK 38).

ANAPTYS ANNOUNCES NEW POSITIVE PHASE 2B TRIAL RESULTS FOR ROSNILIMAB IN RHEUMATOID ARTHRITIS AT ACR LATE-BREAKING ORAL PRESENTATION

NESS-ZIONA, ISRAEL, OCT. 28, 2025 (GLOBE NEWSWIRE) -- ENLIVEX THERAPEUTICS LTD. (NASDAQ: ENLV, THE COMPANY), A CLINICAL-STAGE MACROPHAGE REPROGRAMMING IMMUNOTHERAPY COMPANY, TODAY ANNOUNCED THAT IT WILL PRESENT A LATE-BREAKING POSTER ABSTRACT AT THE AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) CONVERGENCE 2025, TAKING PLACE OCTOBER 2429 AT MCCORMICK PLACE CONVENTION CENTER IN CHICAGO, ILLINOIS.

ENLIVEX THERAPEUTICS TO PRESENT PHASE IIA 3-MONTH DATA OF ALLOCETRA IN PATIENTS WITH MODERATE-TO-SEVERE KNEE OSTEOARTHRITIS AT THE ACR CONVERGENCE 2025

TONMYA DEMONSTRATED SIGNIFICANT REDUCTION IN FIBROMYALGIA PAIN COMPARED WITH PLACEBO IN THE PHASE 3 RESILIENT STUDY TREATMENT WAS WELL TOLERATED WITH MINIMAL EFFECTS ON WEIGHT OR BLOOD PRESSURE AND DISCONTINUATION RATE OF 19% VS. PLACEBO OF 20.8% DATA SUPPORT THE POTENTIAL OF TONMYA AS A WELL-TOLERATED, CENTRALLY ACTING, NON-OPIOID ANALGESIC AND THERAPEUTIC OPTION FOR ADULTS WITH FIBROMYALGIA

TONIX PHARMACEUTICALS PRESENTED DATA ON TONMYA (CYCLOBENZAPRINE HCL SUBLINGUAL TABLETS) AT THE 2025 AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) CONVERGENCE

 ALL MYOSITIS PATIENTS IN THE PHASE 1/2 DM/ASYS COHORT WITH SUFFICIENT FOLLOW-UP WHO MET KEY REGISTRATIONAL INCLUSION CRITERIA EXCEEDED THE REGISTRATIONAL PRIMARY ENDPOINT, DEMONSTRATING MAJOR TIS RESPONSES WITH NO IMMUNOMODULATORS   MYOSITIS REGISTRATIONAL TRIAL BEING INITIATED THIS QUARTER WITH A PLANNED COHORT OF 14 DM/ASYS PATIENTS AND A 16-WEEK PRIMARY ENDPOINT  MODERATE OR MAJOR TIS WHILE OFF IMMUNOMODULATORS AND ON NO OR LOW-DOSE STEROIDS  CONSISTENT WITH FDA ALIGNMENT ON KEY TRIAL PARAMETERS   ALL SYSTEMIC SCLEROSIS PATIENTS WITH SUFFICIENT FOLLOW-UP DEMONSTRATED ONGOING, TRANSFORMATIVE CLINICAL RESPONSES OFF ALL IMMUNOMODULATORS AND STEROIDS   SEVEN OF 8 LUPUS PATIENTS WITH SUFFICIENT FOLLOW-UP ACHIEVED DORIS OR RENAL RESPONSE; RESET-SLE TRIAL EXPANDING TO INCLUDE A NO PRECONDITIONING COHORT WITH INITIAL CLINICAL DATA EXPECTED IN 2026   76 PATIENTS ENROLLED AT 77 CLINICAL TRIAL SITES GLOBALLY AS OF OCTOBER 24, 2025  PHILADELPHIA, OCT. 27, 2025 (GLOBE NEWSWIRE) -- CABALETTA BIO, INC. (NASDAQ: CABA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING AND LAUNCHING THE FIRST CURATIVE TARGETED CELL THERAPIES DESIGNED SPECIFICALLY FOR PATIENTS WITH AUTOIMMUNE DISEASES, TODAY ANNOUNCED POSITIVE CLINICAL DATA AND DEVELOPMENT UPDATES ACROSS THE RESET-MYOSITIS, RESET-SSC AND RESET-SLE TRIALS EVALUATING RESE-CEL (RESECABTAGENE AUTOLEUCEL, FORMERLY KNOWN AS CABA-201). THESE DATA ARE BEING PRESENTED IN MULTIPLE ORAL AND POSTER PRESENTATIONS AT THE ONGOING AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) CONVERGENCE 2025, WHICH IS BEING HELD AT THE MCCORMICK PLACE CONVENTION CENTER IN CHICAGO, ILLINOIS, FROM OCTOBER 24-29, 2025.

CABALETTA BIO PRESENTS POSITIVE CLINICAL DATA AND DEVELOPMENT UPDATES FOR RESE-CEL AT ACR CONVERGENCE 2025

AS OF A SEPTEMBER 25, 2025 DATA CUT-OFF-DATE, 10 PATIENTS WITH TREATMENT-REFRACTORY, MODERATE-TO-SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) WERE TREATED WITH A SINGLE DOSE OF FT819 WITH LESS-INTENSIVE OR NO CONDITIONING CHEMOTHERAPY

FATE THERAPEUTICS PRESENTS NEW CLINICAL DATA AT ACR CONVERGENCE 2025 DEMONSTRATING IMMUNE REMODELING AND DURABLE RESPONSES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH FT819 OFF-THE-SHELF CAR T-CELL THERAPY

CLN-978 LED TO RAPID AND DEEP B CELL DEPLETION IN VITRO AND IN VIVO IN MULTIPLE AUTOIMMUNE DISEASES CAMBRIDGE, MASS., OCT. 25, 2025 (GLOBE NEWSWIRE) -- CULLINAN THERAPEUTICS, INC. (NASDAQ: CGEM), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ACCELERATING POTENTIAL FIRST- OR BEST-IN-CLASS, HIGH-IMPACT THERAPIES IN AUTOIMMUNE DISEASES AND CANCER, WILL PRESENT NEW PRECLINICAL DATA FOR CLN-978, ITS NOVEL INVESTIGATIONAL CD19XCD3 BISPECIFIC T CELL ENGAGER.

CULLINAN THERAPEUTICS SHARES ADDITIONAL PRECLINICAL B CELL DEPLETION DATA FOR CLN-978, SUPPORTING CLINICAL DEVELOPMENT ACROSS MULTIPLE AUTOIMMUNE DISEASES, AT ACR CONVERGENCE 2025

ACRES Commercial Realty

ACR

Price

Dividends

Yield

Dividends

No items found.

Financial Reports

No items found.

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

ACR.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Dividends

Yield

Dividends

No items found.

Financial Reports

No items found.

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

ACR